We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current KALV market cap is 511.74M. The company's latest EPS is USD -2.2022 and P/E is -5.52.
| Quarter End | Oct 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Oct 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -25.88M | -26.95M | -31.73M | -29.09M | -29.75M |
| Net Income | -22.26M | -21.3M | -26.31M | -25.32M | -27.65M |
| Year End April 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 16.13M | 12.69M | 0 | 0 | 0 |
| Operating Income | -29.82M | -40.53M | -57.92M | -96.61M | -110.87M |
| Net Income | -20.82M | -29.12M | -46.24M | -82.34M | -92.91M |
| Quarter End | Oct 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Oct 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 162.84M | 203.47M | 183.2M | 160.33M | 138.74M |
| Total Liabilities | 19.03M | 19.03M | 22.18M | 21M | 24.3M |
| Total Equity | 143.81M | 184.44M | 161.03M | 139.34M | 114.45M |
| Year End April 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 118.13M | 92.53M | 272.01M | 203.88M | 183.2M |
| Total Liabilities | 21.39M | 8.78M | 14.82M | 18.79M | 22.18M |
| Total Equity | 96.74M | 83.75M | 257.19M | 185.09M | 161.03M |
| Quarter End | Oct 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Oct 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -43.34M | -52.63M | -75.26M | -26.73M | -46.56M |
| Investing | 50.14M | 47.63M | 41.42M | 19.61M | 48.17M |
| Financing | 336k | 58.15M | 58.12M | 204k | 332k |
| Year End April 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -36.37M | -44.82M | -30.17M | -78.13M | -75.26M |
| Investing | -69.42M | 16.75M | -147.65M | 57.86M | 41.42M |
| Financing | 87.94M | 11.58M | 212.12M | 1.58M | 58.12M |
| Market Cap | 511.74M |
| Price to Earnings Ratio | -5.52 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 9.11 |
| Price to Book Ratio | 3.18 |
| Dividend Yield | - |
| Shares Outstanding | 42.19M |
| Average Volume (1 week) | 362.2k |
| Average Volume (1 Month) | 351.79k |
| 52 Week Change | 36.14% |
| 52 Week High | 16.88 |
| 52 Week Low | 7.21 |
| Spread (Intraday) | 2.36 (19.11%) |
| Company Name | KalVista Pharmaceuticals Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://www.kalvista.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
